Reprinted with permission from Indiana University News. Mark Bode, Executive Director of Media Relations and Public Affairs. Originally published November 17, 2026.
BLOOMINGTON, Ind. — Richard DiMarchi, Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences in the College of Arts and Sciences at Indiana University Bloomington, has received one of the world’s most prestigious medical research honors, for scientific breakthroughs that have helped transform the treatment of obesity and diabetes.
DiMarchi was named a co-recipient of the 2026 Broermann Medical Innovation Award, an international prize that carries a total award amount of 1 million euros and recognizes research advances with significant impact on human health.
He shares the honor with professor Svetlana Mojsov, of The Rockefeller University in New York, and Matthias H. Tschöp, president of Ludwig Maximilian University in Munich, Germany. The three scientists were recognized for discoveries that contributed to the development of modern GLP-1-based therapies for obesity and diabetes.
“For decades Richard DiMarchi has advanced discoveries that connect fundamental science to transformational patient treatments,” said Caroline Chick Jarrold, interim executive dean of the College and the Herman B Wells Professor of Chemistry. “This global recognition reflects the extraordinary impact of his work on biomedical research, and on the health and wellness of millions of people around the world.”
The award was presented Nov. 17 during a ceremony at the Hessian State Chancellery in Wiesbaden, Germany, by Boris Rhein, minister-president of the German state of Hesse.
“In the last decade, based upon a half century of research, we have progressed with incretin-based medicines to transform the management of excess body weight analogous to historical treatment of excess glucose, cholesterol and blood pressure,” DiMarchi said. “It is providing a transformative advance in public health and patient well-being.”
DiMarchi is widely regarded as one of the world’s leading peptide chemists. He earned his Ph.D. in chemistry from IU in 1979 and then built a career that has bridged academia, industry and entrepreneurship, while helping shape some of the most important advances in modern metabolic medicine.
After early academic research appointments, DiMarchi spent more than two decades at Eli Lilly and Company, playing a key role in developing rDNA-derived human insulin and insulin analogs, advances that helped make diabetes treatments safer, more effective and more precisely matched to millions of patients’ needs. He later returned to IU, where he continues to educate students and scientists, promote novel approaches in peptide synthesis, explore new mechanisms in disease management and collaboratively translate these findings to breakthrough medicines. His work has helped cement IU’s reputation as a powerhouse in life sciences research.
Through his research, DiMarchi has helped pioneer and promote chemical enhanced peptide hormones as drugs, inspiring the development of medicines that are now reshaping treatment options for obesity, diabetes and other endocrine diseases.
Alongside his scientific achievements, DiMarchi has built an exceptional record of innovation and commercialization. He holds more than 100 patents and has co-founded eight successful biotechnology companies, helping translate fundamental research into medicines and therapies with global impact. He is a member of the National Inventors Hall of Fame and the National Academy of Medicine.
“The work of this year’s laureates powerfully proves how pioneering scientific research transforms into medical reality,” said Werner Seeger, chair of the Broermann Award jury. “Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide.”
Established in 2024 by the Broermann Foundation and named for physician and entrepreneur Bernard große Broermann, the Broermann Medical Innovation Award recognizes researchers whose discoveries advance medicine and improve patient care. The award ranks among the highest-endowed medical prizes in the world.